Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 10/20 | 0.50 |
| ▸ | CA2 | P00918 | 10/20 | 0.50 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29154833 | 1.00 | MEN1 (0.61) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL30163663 | 1.00 | MEN1 (0.61) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL4383623 | 0.98 | TDP1 (0.63) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL29832942 | 0.98 | TDP1 (0.63) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL2917277 | 0.95 | MEN1 (0.68) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL28219956 | 0.88 | MEN1 (0.57) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL1654204 | 0.88 | MEN1 (0.57) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL12341542 | 0.86 | MEN1 (0.65) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL19560605 | 0.86 | MEN1 (0.56) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL15679442 | 0.85 | MEN1 (0.59) | MEN1KMT2AGAATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279233-A1 | MACROCYCLIC TAK1 INHIBITORS | AQILION AB (SE) | 2024-08-22 | — | — | US | disclosed |
| EP-4363422-A1 | MACROCYCLIC TAK1 INHIBITORS | Aqilion AB (SE) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023275199-A1 | MACROCYCLIC TAK1 INHIBITORS | AQILION AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| EP-3366680-B1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES INC (US) | 2020-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279233-A1 | MACROCYCLIC TAK1 INHIBITORS | TAB1, TBK1, IRAK3 | MEN1 317/4885KMT2A 1921/4885GAA 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.